The capacity for Alzheimer's disease confirmatory testing in the United States: The current situation and simulations for future increase.

ABSTRACT: BackgroundWith recent advances in disease-modifying therapies for Alzheimer's disease (AD), demand for confirmatory biomarker testing such as via cerebrospinal fluid (CSF) analysis or amyloid positron emission tomography (PET) will increase considerably for diagnosis.ObjectiveTo assess the current capacity and estimating the anticipated future need of AD confirmatory testing in the United States (US).MethodsA population-based decision tree model was employed to simulate the AD diagnostic pathway for patients presenting with symptoms of mild cognitive impairment or mild dementia in primary and secondary care in the US. All patients were assumed to be enrolled in Medicare. The study was conducted from the US payer's perspective over a 5-year period. Four scenarios assessed the impact of diff

SUBMITTER: Roth S 

PROVIDER: S-EPMC12855613 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature